<p>加利福尼亚州南旧金山，2025 年 12 月 10 日（全球新闻通讯社）——Denali Therapeutics Inc.（纳斯达克代码：DNLI）今天宣布其承销的公开发行价格为 9,142,857 股普通股，公众发行价格为每股 17.50 美元，并且为了某些投资者提供预先融资的认股权证，以购买 2,285,714 股普通股，价格为每个预先融资的认股权证 17.49 美元，这代表了每股普通股的公众发行价格减去每个预先融资的认股权证的 0.01 美元行使价格。所有股份和预先融资的认股权证均由 Denali Therapeutics 出售。此外，Denali Therapeutics 已授予承销商一个 30 天的选择权，以购买最多 1,714,285 股其普通股。Denali Therapeutics 预计在扣除承销折扣和佣金及其他发行费用之前，将获得约 2 亿美元的总毛收益，并且不包括承销商选择购买额外股份的任何行使。该发行预计将在 2025 年 12 月 11 日左右完成，具体取决于满足惯常的交割条件。</p>
<p>高盛公司、摩根大通证券公司、摩根士丹利公司和杰富瑞公司作为此次发行的联合账簿管理人。H.C. Wainwright &amp; Co., LLC 和 B. Riley Securities, Inc.作为此次发行的共同管理人。</p>
<p>Denali Therapeutics 提交了一份 S-3 表格的注册声明，该声明在 2025 年 2 月 27 日提交给 SEC 时自动生效，并于 2025 年 12 月 9 日提交了与此次发行相关的初步招股说明书补充和随附招股说明书。与此次发行相关的最终招股说明书补充和随附招股说明书也将提交给 SEC。这些文件可以通过 SEC 的网站 www.sec.gov 免费获取。</p>
<p>一旦可用，与此次发行相关的最终招股说明书补充和随附招股说明书的副本也可以从以下地址获得：</p>
<p>高盛公司，注意：招股说明书部，200 West Street, New York, NY 10282，电话：1-866-471-2526，传真：212-902-9316，电子邮件：prospectus-ny@ny.email.gs.com；摩根大通证券公司，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股说明书部，180 Varick Street, 2nd Floor, New York, NY 10014，电话：1-866-718-1649，电子邮件：prospectus@morganstanley.com；杰富瑞公司，注意：股权承销招股说明书部，520 Madison Avenue, New York, New York 10022，电话：（877）821-7388，电子邮件：Prospectus_Department@Jefferies.com。</p>
<p>本新闻稿不构成出售要约或购买要约的招揽，也不会在任何州或其他管辖区进行这些证券的销售，除非在该州或管辖区的证券法下注册或合格之前，该要约、招揽或销售是非法的。</p>
<p><strong>关于 Denali Therapeutics</strong></p>
<p>Denali Therapeutics 是一家生物技术公司，开创了一种新型生物治疗药物，旨在利用其专有的 TransportVehicle™平台跨越血脑屏障。凭借经过临床验证的递送平台和不断增长的治疗候选药物组合，Denali Therapeutics 正朝着提供有效药物的目标迈进，以改变生活在神经退行性疾病、溶酶体储存疾病和其他严重疾病患者的生活。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据联邦证券法的定义的前瞻性声明。这些声明涉及风险和不确定性，可能导致实际结果与预期结果有重大差异，包括但不限于，Denali Therapeutics 是否能够通过普通股和预先融资的认股权证的销售筹集资金或完成此次发行、发行的最终条款、满足惯常的交割条件、市场条件、预期的发行收益的使用，这可能因市场条件或其他原因而变化，以及美国或国际上的一般经济、行业或政治条件的影响。与此次发行、Denali Therapeutics 及其业务相关的其他风险和不确定性可以在 Denali Therapeutics 最近提交给 SEC 的当前、季度和年度报告的 “风险因素” 部分以及与此次发行相关的初步招股说明书补充和随附招股说明书中找到。Denali Therapeutics 不承担更新或修订任何前瞻性声明的责任或义务。</p>
<p><strong>投资者关系联系人：</strong></p>
<p>劳拉·汉森，博士。</p>
<p>投资者关系副总裁</p>
<p><strong>hansen@dnli.com</strong></p>
<p><strong>媒体联系人：</strong></p>
<p>艾琳·帕顿</p>
<p>企业传播</p>
<p><strong>epatton@dnli.com</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png"/></p>

DNLI

<p>Denali Therapeutics 宣布以每股 17.50 美元的价格公开发行 9,142,857 股普通股，并以每股 17.49 美元的价格发行 2,285,714 股预付认股权证。此次发行旨在筹集约 2 亿美元，预计于 2025 年 12 月 11 日完成。高盛、摩根大通、摩根士丹利和杰富瑞负责管理此次发行。该公司已向美国证券交易委员会（SEC）提交了必要文件，并在前瞻性声明中强调了风险</p>

<p>SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 11, 2025, subject to satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>加利福尼亚州南旧金山，2025 年 12 月 10 日（全球新闻通讯社）——Denali Therapeutics Inc.（纳斯达克代码：DNLI）今天宣布其承销的公开发行价格为 9,142,857 股普通股，公众发行价格为每股 17.50 美元，并且为了某些投资者提供预先融资的认股权证，以购买 2,285,714 股普通股，价格为每个预先融资的认股权证 17.49 美元，这代表了每股普通股的公众发行价格减去每个预先融资的认股权证的 0.01 美元行使价格。所有股份和预先融资的认股权证均由 Denali Therapeutics 出售。此外，Denali Therapeutics 已授予承销商一个 30 天的选择权，以购买最多 1,714,285 股其普通股。Denali Therapeutics 预计在扣除承销折扣和佣金及其他发行费用之前，将获得约 2 亿美元的总毛收益，并且不包括承销商选择购买额外股份的任何行使。该发行预计将在 2025 年 12 月 11 日左右完成，具体取决于满足惯常的交割条件。</p>
</div><p>Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. H.C. Wainwright &amp; Co., LLC and B. Riley Securities, Inc. are acting as co-managers for the offering.</p>
<div class="lb-trans"><p>高盛公司、摩根大通证券公司、摩根士丹利公司和杰富瑞公司作为此次发行的联合账簿管理人。H.C. Wainwright &amp; Co., LLC 和 B. Riley Securities, Inc.作为此次发行的共同管理人。</p>
</div><p>Denali Therapeutics filed a Registration Statement on Form S-3, which was automatically effective upon filing with the SEC on February 27, 2025, and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering on December 9, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>Denali Therapeutics 提交了一份 S-3 表格的注册声明，该声明在 2025 年 2 月 27 日提交给 SEC 时自动生效，并于 2025 年 12 月 9 日提交了与此次发行相关的初步招股说明书补充和随附招股说明书。与此次发行相关的最终招股说明书补充和随附招股说明书也将提交给 SEC。这些文件可以通过 SEC 的网站 www.sec.gov 免费获取。</p>
</div><p>When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:</p>
<div class="lb-trans"><p>一旦可用，与此次发行相关的最终招股说明书补充和随附招股说明书的副本也可以从以下地址获得：</p>
</div><p>Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, telephone: 1-866-718-1649, email: prospectus@morganstanley.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com.</p>
<div class="lb-trans"><p>高盛公司，注意：招股说明书部，200 West Street, New York, NY 10282，电话：1-866-471-2526，传真：212-902-9316，电子邮件：prospectus-ny@ny.email.gs.com；摩根大通证券公司，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股说明书部，180 Varick Street, 2nd Floor, New York, NY 10014，电话：1-866-718-1649，电子邮件：prospectus@morganstanley.com；杰富瑞公司，注意：股权承销招股说明书部，520 Madison Avenue, New York, New York 10022，电话：（877）821-7388，电子邮件：Prospectus_Department@Jefferies.com。</p>
</div><p>This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的招揽，也不会在任何州或其他管辖区进行这些证券的销售，除非在该州或管辖区的证券法下注册或合格之前，该要约、招揽或销售是非法的。</p>
</div><p><strong>About Denali Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Denali Therapeutics</strong></p>
</div><p>Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali Therapeutics is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases.</p>
<div class="lb-trans"><p>Denali Therapeutics 是一家生物技术公司，开创了一种新型生物治疗药物，旨在利用其专有的 TransportVehicle™平台跨越血脑屏障。凭借经过临床验证的递送平台和不断增长的治疗候选药物组合，Denali Therapeutics 正朝着提供有效药物的目标迈进，以改变生活在神经退行性疾病、溶酶体储存疾病和其他严重疾病患者的生活。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Denali Therapeutics will be able to raise capital through the sale of shares of common stock and pre-funded warrants or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the offering, Denali Therapeutics and its business can be found under the heading “Risk Factors” in Denali Therapeutics’ most recent current, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Denali Therapeutics assumes no duty or obligation to update or revise any forward-looking statements for any reason.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法的定义的前瞻性声明。这些声明涉及风险和不确定性，可能导致实际结果与预期结果有重大差异，包括但不限于，Denali Therapeutics 是否能够通过普通股和预先融资的认股权证的销售筹集资金或完成此次发行、发行的最终条款、满足惯常的交割条件、市场条件、预期的发行收益的使用，这可能因市场条件或其他原因而变化，以及美国或国际上的一般经济、行业或政治条件的影响。与此次发行、Denali Therapeutics 及其业务相关的其他风险和不确定性可以在 Denali Therapeutics 最近提交给 SEC 的当前、季度和年度报告的 “风险因素” 部分以及与此次发行相关的初步招股说明书补充和随附招股说明书中找到。Denali Therapeutics 不承担更新或修订任何前瞻性声明的责任或义务。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者关系联系人：</strong></p>
</div><p>Laura Hansen, Ph.D.</p>
<div class="lb-trans"><p>劳拉·汉森，博士。</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>投资者关系副总裁</p>
</div><p><strong>hansen@dnli.com</strong></p>
<div class="lb-trans"><p><strong>hansen@dnli.com</strong></p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系人：</strong></p>
</div><p>Erin Patton</p>
<div class="lb-trans"><p>艾琳·帕顿</p>
</div><p>Corporate Communications</p>
<div class="lb-trans"><p>企业传播</p>
</div><p><strong>epatton@dnli.com</strong></p>
<div class="lb-trans"><p><strong>epatton@dnli.com</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg4OSM3MzE1MTE5IzIwOTM0Njg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png"/></p>

Denali Therapeutics 宣布普通股和预付款认股权证公开发行的定价 | DNLI 股票新闻